US-based medical technology company Medtronic has received CE mark approval for its Resolute Onyx Drug-Eluting Stent (DES).
Launched internationally, the first live patient implant of the Resolute Onyx DES occurred during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain.
Medtronic coronary and renal denervation business unit general manager and vice-president Jason Weidman said: "CoreWire Technology is an exciting innovation that will have measurable impact on clinical practice today and tomorrow.
"The advancements of the Resolute Onyx DES specifically address the need for continued procedural efficiency and ease-of-use. Importantly, and in contrast to some current DES technologies, it achieves meaningful deliverability enhancement with no compromise to stent strength."
Resolute Onyx DES features CoreWire technology, which allows it to have a denser core metal wrapped in a cobalt alloy outer layer, and helps to increase radiopacity.
It also includes a new delivery system with PowerTrac technology, which was launched earlier this year with the NC Euphora Noncompliant Balloon Dilatation Catheter.
Medtronic noted that CoreWire technology is the new DES advancement after Continuous Sinusoid Technology (CST), which was previously introduced with the Resolute Integrity DES and the Integrity bare-metal stent.
The product has not received approval in the US, said Medtronic.
Image: Medtronic’s world headquarters in Fridley, Minnesota, US. Photo: courtesy of Bobak Ha’Eri.